Watch: What makes our immunotherapies different on the growing myeloma treatment market

The multiple myeloma treatment market is large, and growing; As the second most common haematological cancer worldwide, SEER estimates 34,920 new cases annually in the US alone (2021), and a European incidence roughly equivalent.

Multiple myeloma is a chronic and incurable disease characterised by repeated relapse, with a poor prognosis. Medical experts universally agree we need more effective treatment targets.

With our patent-protected technology, HaemaLogiX is developing a suite of immunotherapies across the multiple myeloma treatment landscape.

Video: What makes our immunotherapies different on the large and growing multiple myeloma treatment market